AIMS: High-density lipoproteins (HDL) exert striking anti-inflammatory effects and emerging evidence suggests that they may augment ischaemia-mediated neovascularization. We sought to determine whether HDL conditionally regulates angiogenesis, depending on the pathophysiological context by (i) inhibiting inflammation-induced angiogenesis, but also; (ii) enhancing ischaemia-mediated angiogenesis. METHODS AND RESULTS: Intravenously delivered apolipoprotein (apo) A-I attenuated neovascularization in the murine femoral collar model of inflammation-induced angiogenesis, compared with phosphate-buffered saline infused C57BL6/J mice (58%), P < 0.05. Conversely, apoA-I delivery augmented neovessel formation (75%) and enhanced blood perfusion (45%) in the murine hindlimb ischaemia model, P < 0.05. Reconstituted HDL (rHDL) was tested on key angiogenic cell functions in vitro. rHDL inhibited human coronary artery endothelial cell migration (37.9 and 76.9%), proliferation (15.7 and 40.4%), and tubulogenesis on matrigel (52 and 98.7%) when exposed to two inflammatory stimuli: tumour necrosis factor-α (TNF-α) and macrophage-conditioned media (MCM). In contrast, rHDL significantly augmented hypoxia-stimulated migration (36.9%), proliferation (135%), and tubulogenesis (22.9%), P < 0.05. Western blot and RT-PCR analyses revealed that these divergent actions of rHDL were associated with conditional regulation of hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and VEGF receptor 2, which were attenuated in response to TNF-α (40.4, 41.0, and 33.2%) and MCM (72.5, 30.7, and 69.5%), but augmented by rHDL in hypoxia (39.8, 152.6, and 15.7%%), all P < 0.05. CONCLUSION: HDL differentially regulates angiogenesis dependent upon the pathophysiological setting, characterized by suppression of inflammation-associated angiogenesis, and conversely, by the enhancement of hypoxia-mediated angiogenesis. This has significant implications for therapeutic modulation of neovascularization.
AIMS: High-density lipoproteins (HDL) exert striking anti-inflammatory effects and emerging evidence suggests that they may augment ischaemia-mediated neovascularization. We sought to determine whether HDL conditionally regulates angiogenesis, depending on the pathophysiological context by (i) inhibiting inflammation-induced angiogenesis, but also; (ii) enhancing ischaemia-mediated angiogenesis. METHODS AND RESULTS: Intravenously delivered apolipoprotein (apo) A-I attenuated neovascularization in the murine femoral collar model of inflammation-induced angiogenesis, compared with phosphate-buffered saline infused C57BL6/J mice (58%), P < 0.05. Conversely, apoA-I delivery augmented neovessel formation (75%) and enhanced blood perfusion (45%) in the murine hindlimb ischaemia model, P < 0.05. Reconstituted HDL (rHDL) was tested on key angiogenic cell functions in vitro. rHDL inhibited human coronary artery endothelial cell migration (37.9 and 76.9%), proliferation (15.7 and 40.4%), and tubulogenesis on matrigel (52 and 98.7%) when exposed to two inflammatory stimuli: tumour necrosis factor-α (TNF-α) and macrophage-conditioned media (MCM). In contrast, rHDL significantly augmented hypoxia-stimulated migration (36.9%), proliferation (135%), and tubulogenesis (22.9%), P < 0.05. Western blot and RT-PCR analyses revealed that these divergent actions of rHDL were associated with conditional regulation of hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and VEGF receptor 2, which were attenuated in response to TNF-α (40.4, 41.0, and 33.2%) and MCM (72.5, 30.7, and 69.5%), but augmented by rHDL in hypoxia (39.8, 152.6, and 15.7%%), all P < 0.05. CONCLUSION: HDL differentially regulates angiogenesis dependent upon the pathophysiological setting, characterized by suppression of inflammation-associated angiogenesis, and conversely, by the enhancement of hypoxia-mediated angiogenesis. This has significant implications for therapeutic modulation of neovascularization.
Authors: Roberto S Moreira; Maria C Irigoyen; Jose M C Capcha; Talita R Sanches; Paulo S Gutierrez; Margoth R Garnica; Irene de L Noronha; Lucia Andrade Journal: Am J Physiol Regul Integr Comp Physiol Date: 2020-01-22 Impact factor: 3.619
Authors: Samuel T Hourigan; Emma L Solly; Victoria A Nankivell; Anisyah Ridiandries; Benjamin M Weimann; Rodney Henriquez; Edward R Tepper; Jennifer Q J Zhang; Tania Tsatralis; Zoe E Clayton; Laura Z Vanags; Stacy Robertson; Stephen J Nicholls; Martin K C Ng; Christina A Bursill; Joanne T M Tan Journal: Sci Rep Date: 2018-09-11 Impact factor: 4.379
Authors: Kaitlin R Morrison; Emma L Solly; Tomer Shemesh; Peter J Psaltis; Stephen J Nicholls; Alex Brown; Christina A Bursill; Joanne T M Tan Journal: Diabetologia Date: 2021-03-02 Impact factor: 10.122
Authors: Tania Tsatralis; Anisyah Ridiandries; Stacy Robertson; Laura Z Vanags; Yuen Ting Lam; Joanne T M Tan; Martin K C Ng; Christina A Bursill Journal: Lipids Health Dis Date: 2016-09-06 Impact factor: 3.876
Authors: Dhanya Ravindran; Anisyah Ridiandries; Laura Z Vanags; Rodney Henriquez; Siân Cartland; Joanne T M Tan; Christina A Bursill Journal: PLoS One Date: 2017-03-10 Impact factor: 3.240
Authors: Tom Alsaigh; Belinda A Di Bartolo; Jocelyne Mulangala; Gemma A Figtree; Nicholas J Leeper Journal: Circ Res Date: 2021-06-10 Impact factor: 23.213
Authors: Zahra Lotfollahi; Joseph Dawson; Robert Fitridge; Christina Bursill Journal: Adv Wound Care (New Rochelle) Date: 2021-01-21 Impact factor: 4.947